# Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

> **NCT03444506** · PHASE2 · COMPLETED · sponsor: **Glenmark Pharmaceuticals Ltd. India** · enrollment: 180 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Molo 1 (also referred as GSP 301-2 NS)
- **DRUG:** Molo 2 (also referred as GSP 301-1 NS)
- **DRUG:** Placebo nasal spray
- **DRUG:** DYMISTA nasal spray
- **DRUG:** PATANASE nasal spray

## Key facts

- **NCT ID:** NCT03444506
- **Lead sponsor:** Glenmark Pharmaceuticals Ltd. India
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-27
- **Primary completion:** 2014-02-28
- **Final completion:** 2014-02-28
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444506, "Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03444506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*